Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Down 13.3% in November

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 25,500 shares, a decline of 13.3% from the October 31st total of 29,400 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily volume of 41,600 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DARE. Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Daré Bioscience in a research report on Friday, November 15th.

Daré Bioscience Trading Down 0.6 %

NASDAQ DARE traded down $0.02 on Tuesday, reaching $3.28. The company had a trading volume of 52,295 shares, compared to its average volume of 46,893. The stock’s 50 day moving average is $3.55 and its 200-day moving average is $3.87. Daré Bioscience has a 52 week low of $3.05 and a 52 week high of $7.56.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.